Photodermatology, photoimmunology & photomedicine · 2026
Clinical Efficacy of 5-Aminolevulinic Acid Photodynamic Therapy Combined With Interferon Spray in Treating Common and Plantar Warts.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Sheng-Jiang, Miao Jia-Min, Zheng Jie-Cheng, Feng Shuang, Zhao Yan-Yan, Zhang Yang-Bing, Chen Jian-Hua, Jin Yu-Dan, Liao Jia
Аннотация
BACKGROUND: Conventional treatments for common and plantar warts often have limited efficacy and high recurrence rates. 5-Aminolevulinic acid photodynamic therapy (5-ALA-PDT) has attracted increasing attention as an alternative therapeutic option for these lesions. This study investigated the potential of 5-ALA-PDT as an alternative treatment option for patients with refractory common and plantar warts.
OBJECTIVE: To explore the clinical efficacy of 5-ALA-PDT and recombinant human interferon alpha 2b (rhIFN-α2b) spray combination therapy against common and plantar warts.
METHODS: We enrolled 104 patients with common or plantar warts and randomly assigned them to the intervention (5-ALA-PDT combined with rhIFN-α2b spray; n = 51) or control (cryotherapy; n = 53) group to compare treatment efficacy, recurrence rate, and adverse events.
RESULTS: After three consecutive treatment cycles, the 4-week complete recovery and total effective rates were 90.20% and 96.08% in the intervention group, versus 62.26% (p = 0.002) and 77.36% (p = 0.013) in the control group. Recurrence rates were significantly lower in the intervention group at 8 weeks (2.17% vs. 24.24%), 12 weeks (4.35% vs. 33.33%), and 6 months (4.35% vs. 39.39%; all p < 0.05). All adverse events were mild to moderate and localized.
CONCLUSION: 5-ALA-PDT combined with rhIFN-α2b spray exhibited superior clinical efficacy in treating common and plantar warts, significantly improving treatment efficacy, reducing medium-term recurrence, and demonstrating good safety and tolerability.
OBJECTIVE: To explore the clinical efficacy of 5-ALA-PDT and recombinant human interferon alpha 2b (rhIFN-α2b) spray combination therapy against common and plantar warts.
METHODS: We enrolled 104 patients with common or plantar warts and randomly assigned them to the intervention (5-ALA-PDT combined with rhIFN-α2b spray; n = 51) or control (cryotherapy; n = 53) group to compare treatment efficacy, recurrence rate, and adverse events.
RESULTS: After three consecutive treatment cycles, the 4-week complete recovery and total effective rates were 90.20% and 96.08% in the intervention group, versus 62.26% (p = 0.002) and 77.36% (p = 0.013) in the control group. Recurrence rates were significantly lower in the intervention group at 8 weeks (2.17% vs. 24.24%), 12 weeks (4.35% vs. 33.33%), and 6 months (4.35% vs. 39.39%; all p < 0.05). All adverse events were mild to moderate and localized.
CONCLUSION: 5-ALA-PDT combined with rhIFN-α2b spray exhibited superior clinical efficacy in treating common and plantar warts, significantly improving treatment efficacy, reducing medium-term recurrence, and demonstrating good safety and tolerability.